Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

SpingWorks

- PMLiVE

NICE recommends BMS and Pfizer’s Eliquis for blood clots

Will be a treatment option for venous thromboembolism

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

Bristol-Myers Squibb (BMS) building

BMS buys immunotherapy specialist Flexus in $1.2bn deal

And signs new cancer research partnership with Rigel

National Institute for Health and Care Excellence NICE logo

Good NICE news for Pfizer, but Dendreon drug rejected

Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not

- PMLiVE

Early win for Pfizer as Remicade biosimilar launches in West Europe

Hospira launchescopycat version of Janssen/MSD’s drug in major European markets

- PMLiVE

Pfizer UK appoints Erik Nordkamp as new managing director

He takes over from Jonathan Emms who moves to a global role within the firm

- PMLiVE

Pfizer’s bid for Hospira could lead to break-up

Questions posed whether $15bn bid will be profitable for the firm

- PMLiVE

Pfizer’s Ibrance wins early breast cancer approval in US

FDA’s decision come two months ahead of schedule

- PMLiVE

Products over pipeline in Pfizer’s acquisition targets, hints CEO

Sale forecasts for 2015 are down by up to $5bn compared to last year

- PMLiVE

Pfizer’s Prevenar 13 price cut slammed by MSF

Global health charity says reduction of 20 cents is "negligible"

Pfizer strikes genetic research deal with 23andMe

Lupus study and research community forms just one part of their collaboration

- PMLiVE

Pfizer names head of Germany business

Peter Albiez has been with pharma company since 1996

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links